Cargando…
Discovery and SAR of Novel 2,3‐Dihydroimidazo[1,2‐c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80‐6946)
The phosphoinositide 3‐kinase (PI3K) pathway is aberrantly activated in many disease states, including tumor cells, either by growth factor receptor tyrosine kinases or by the genetic mutation and amplification of key pathway components. A variety of PI3K isoforms play differential roles in cancers....
Autores principales: | Scott, William J., Hentemann, Martin F., Rowley, R. Bruce, Bull, Cathy O., Jenkins, Susan, Bullion, Ann M., Johnson, Jeffrey, Redman, Anikó, Robbins, Arthur H., Esler, William, Fracasso, R. Paul, Garrison, Timothy, Hamilton, Mark, Michels, Martin, Wood, Jill E., Wilkie, Dean P., Xiao, Hong, Levy, Joan, Stasik, Enrico, Liu, Ningshu, Schaefer, Martina, Brands, Michael, Lefranc, Julien |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094563/ https://www.ncbi.nlm.nih.gov/pubmed/27310202 http://dx.doi.org/10.1002/cmdc.201600148 |
Ejemplares similares
-
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
por: Patnaik, A., et al.
Publicado: (2016) -
5-(4-Methylphenyl)-2,3-diphenyl-5,6-dihydroimidazo[1,2-c]quinazoline
por: Zhang, Jiankang, et al.
Publicado: (2010) -
Pharmacokinetics of intravenous pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor [(14)C]copanlisib (BAY 80-6946) in a mass balance study in healthy male volunteers
por: Gerisch, Michael, et al.
Publicado: (2017) -
Update on the role of copanlisib in hematologic malignancies
por: Le, Thuy, et al.
Publicado: (2021) -
Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives
por: Munoz, Javier, et al.
Publicado: (2021)